Uromigos Live 2023: NMIBC Updates
By The Uromigos - Last Updated: November 20, 2023During the second-annual Uromigos Live & Unplugged event, Thomas Powles, MBBS, MRCP, MD; Petros Grivas, MD, PhD; Sia Daneshmand, MD; and Sam Chang, MD, MBA, discussed the latest updates in non-muscle invasive bladder cancer.
Therapies under consideration included nadofaragene firadenovec, pembrolizumab, IL-15 superagonist, atezolizumab, TAR-200, TAR-210, and more.
View the first bladder cancer session of the day on the latest data and updates in frontline bladder cancer.
Post Tags:Uromigos Live 2023-Bladder Cancer
Related Posts
Dr. Powles chaired a livestreamed RCC session that included lively discussion from Drs. Atkins, McDermott, and Rini.
The panel highlights a serious of relevant studies in renal cell carcinoma, including CONTACT-03 and TiNivo-2.
The panel discusses data related to RLTs in prostate cancer, including a recap of the VISION trial and the PSMAfore trial.
The panel breaks down the details of the PROpel, TALAPRO-2, and MAGNITUDE trials along with relevant rPFS and HR data.
The panel discussed the latest data and updates in frontline bladder cancer during a livestreamed session.
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.